British Journal of Cancer · 2014 · 110 citations · 43 references
MedicineMolecular BiologyOncologyCell SignalingMolecular OncologySignal TransductionBrain TumorsCancer Cell SignalingCancer ProgressionGlioblastomaIntegrin SignalingOncogenic Signaling PathwaysCell InvasionErk SignalingImmunofluorescence AssaysIntegrin BindingIntegrin Signaling In CancerIntegrin-ligand BindingTemozolomide TherapyWestern Blot Analysis
BACKGROUND: Insulin-like growth factor binding protein-2 (IGFBP-2) is significantly increased in the serum of patients with malignant gliomas. High plasma IGFBP-2 levels are correlated with poor prognosis in glioma patients. However, the exact role of exogenous IGFBP-2 in gliomas is unclear. METHODS AND RESULTS: Using the MTT cell viability assay, cell cycle analysis, and the transwell migration assay, it was demonstrated that IGFBP-2 treatment stimulated proliferation and invasion in U87 and U251 cell lines and primary SU3 glioma cells. Western blot analysis and immunofluorescence staining revealed that IGFBP-2 promoted ERK phosphorylation and nuclear translocation. Moreover, blocking ERK activation using the inhibitor PD98059 markedly reduced the effects of IGFBP-2 in glioma cells. As IGFBP-2 has an integrin-binding domain, the contribution of integrin β1 to these IGFBP-2-mediated processes was examined. Neutralisation or knockdown of the expression of integrin β1 inhibited IGFBP-2-induced ERK activation, cell proliferation, and cell invasion. Significantly, IGFBP-2 induced temozolomide resistance in glioma cells in an integrin β1/ERK-dependent manner. CONCLUSIONS: Exogenous IGFBP-2 induces proliferation, invasion, and chemoresistance in glioma cells via integrin β1/ERK signaling, suggesting that targeting this pathway could represent a potential therapeutic strategy for the treatment of gliomas. The identification of this pathway in glioma progression provides insight into the mechanism by which serum IGFBP-2 levels can predict the prognosis of glioma patients.
43
Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Roger Stupp, Warren Mason, Martin J. van den Bent et al. · New England Journal of Medicine · 2005 · 21.6K citations · Full text
Neuronal and glioma-derived stem cell factor induces angiogenesis within the brain
Lixin Sun, Ai-Min Hui, Qin Su et al. · Cancer Cell · 2006 · 903 citations · Full text
Medicine, Neurobiology, Neuroscience +10
Seizure‐Promoting Effect of Blood–Brain Barrier Disruption
Nicola Marchi, Lilyana Angelov, T. Masaryk et al. · Epilepsia · 2007 · 499 citations · Full text
Tumour-infiltrating CD4+ and CD8+ lymphocytes as predictors of clinical outcome in glioma
Sheng Han, C Zhang, Q Li et al. · British Journal of Cancer · 2014 · 361 citations · Full text
Life Sciences, Immunology, Oncology +17